Usage and cost of first-line drugs for patients referred to inpatient anthroposophic integrative care or inpatient conventional care for stress-related mental disorders—a register based study by Tobias Sundberg et al.
Sundberg et al. BMC Complementary and Alternative Medicine  (2015) 15:354 
DOI 10.1186/s12906-015-0865-3RESEARCH ARTICLE Open AccessUsage and cost of first-line drugs for patients
referred to inpatient anthroposophic integrative
care or inpatient conventional care for
stress-related mental disorders—a register based
study
Tobias Sundberg1,2*, Laith Hussain-Alkhateeb3,4 and Torkel Falkenberg1,2Abstract
Background: Stress-related mental disorders (SRMD) are common and costly. Rehabilitation strategies, including
pharmacotherapy, may be complicated to evaluate. Previous research has indicated increased quality of life and
self-rated health for SRMD patients that receive a combination of conventional and complementary therapies, i.e.
integrative care. The aim of this retrospective registry study was to explore and contrast the prescription of first-line
drugs for SRMD patients referred to hospital inpatient anthroposophic integrative care (AIC) or inpatient
conventional care (CC).
Methods: SRMD patients that had received AIC or CC were identified through high-quality inpatient registry
data from Stockholm County Council and matched by available background characteristics including diagnosis
(ICD-10: F43), age, gender and socio-economics. General disease load was estimated by analysis of ICD-10
chapter data. The Swedish Prescribed Drug Register was then used to investigate purchased defined daily
doses (DDD) and cost of drugs from 90-days before/after, and 180-days before/after, the first visits (index) to
AIC and CC respectively. First-line drug categories were Anatomical Therapeutic Chemical classification codes
N05A (antipsychotics), N05B (anxiolytics), N05C (hypnotics and sedatives) and N06A (antidepressants).
Results: There were no statistically significant differences between the AIC (n = 161) and the CC (n = 1571)
cohorts in terms of background characteristics and the overall disease loads were similar between the groups
the preceding year. At baseline, the prescription of first-line anxiolytics and antidepressants were not
statistically different between groups whereas the prescription of antipsychotics and hypnotics/sedatives were
lower for the AIC cohort. The overall change in drug prescriptions and costs during the investigated periods,
both for the 90-days before/after and for the 180-days before/after the index visit, showed a general decrease
within the AIC cohort with significantly less prescribed anxiolytics and hypnotics/sedatives. During the same
time periods there was a general increase in prescriptions and costs of first-line drugs within the CC cohort.
The overall disease loads were generally stable within both cohorts over time, except that the CC cohort had
increased visits registered with an ICD-10 F-chapter diagnosis the year after index.
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Conclusions: The results suggests that there may be different drug utilization patterns for SRMD patients
referred to AIC or CC. Different management strategies between AIC and CC providers, different SRMD
disease severities and different preferences of patients referred to AIC and CC are hypothetical differentiating
factors that may influence drug outcomes over time. Additional studies including prospective and randomized
clinical trials are warranted to determine if there is a causal link between inpatient AIC and reduced drug
utilization.Background
Mental ill health
The individual and societal burdens of mental ill health,
including stress related mental disorders (SRMD), are
significant. The concept of SRMD, referring to code F43
in the International Classification of Diseases version 10
(ICD-10), involves short- and long-term reactions to
severe stress including post-traumatic stress disorders,
adjustment disorders with depressive reactions and other
reactions to severe stress such as exhaustion disorder or
other emotional disturbances [1, 2].
Evidence of the heavy burden of mental ill health in
Sweden can be found in the increase and predominance
of psychological disorders among people with sickness
absence and those receiving compensation for sickness
or activity loss [3, 4]. For new sickness and activity
compensation in Sweden in 2012, psychological disor-
ders constituted the most prevalent diagnostic group
among both women and men across almost every age
group, ranging from 25 to 30 % among those granted
compensation in the oldest age group, up to 85 % in
the youngest age group [3].
The Swedish National Board of Health and Welfare has
estimated that 20-40 % of the population suffer from
mental ill health, ranging from mild to severe disorders
[5]. The prevalence of SRMD varies among different disor-
ders and contexts. In Sweden e.g. the life-time prevalence
of post-traumatic stress disorder in the general population
has been estimated at about 6 %, with twice as many
women as men affected [6]. Similarly, prevalence figures of
up to 20 % have been reported for perceived exhaustion
and related symptoms [5, 7, 8], with an estimated ratio of
1:2 for self-reported exhaustion among men and women
respectively [9].Costs
It is difficult to estimate the specific costs for SRMD alone
compared to other psychiatric diagnoses. The annual cost
of psychiatric disorders in Sweden has been estimated at
euro (EUR) 9.4 billion, where the sum of direct costs,
including the cost of drugs, comprises approximately 20 %
of the total costs [10]. Specifically, regarding first-line
drugs targeting psychiatric disorders, defined as phar-
macy sales price excluding VAT, it has been estimated thatantidepressants comprise almost 60 % of the total drug
costs followed by antipsychotics, hypnotics, sedatives and
anxiolytics [10]. The Swedish Dental and Pharmaceutical
Benefits Agency (TLV), a central government agency that
determines whether a pharmaceutical product shall be
subsidized by the state, has specifically investigated the
use of antidepressants, i.e. the ATC-N06A drug group, in
terms of costs and effects [11]. In short, the TLV reported
that 700 000 people were treated with antidepressants in
2007; that the associated costs for antidepressant pharma-
cotherapy was high; that less than every second patient
reached a satisfactory treatment result from the initial
antidepressant treatment; that adverse drug events are
problematic and may contribute to patients not being able
to fulfil or continue their treatments; and that more effect-
ive drugs and more knowledge how to use these drugs are
needed [11]. TLV concludes that there are gaps in the
evidence in healthcare to make decisions about effect-
ive treatment – not least to put antidepressant drugs in
relation to other forms of treatment – and that more
knowledge about these drugs is needed for patients to
get effective treatment [11].Managing SRMD
Conclusive evidence-based clinical guidelines for man-
aging SRMD in Sweden are currently lacking [2].
Hence, conventional management of SRMD is mainly
consensus-based and generally recommends multi-modal
and multi-professional rehabilitation, which may include
psychological and group counselling, individually tailored
stress reduction methods alongside support for lifestyle
changes and workplace interaction [2, 12, 13]. Such re-
habilitation strategies may be complemented by pharma-
cotherapy for anxiety, sleeping problems and depressive
reactions, e.g. using anxiolytics, sedatives and antidepres-
sants [13]. Pharmacotherapy with anxiolytics and sedatives
should generally be administered at low doses and used
infrequently as needed [13]. Antidepressants, if indicated,
are typically prescribed in the long term with follow-ups
after 1, 6 and 12 months [13]. Sick-leave or physical activ-
ity can also be part of the rehabilitation plan [13].
Integrative care aims to adhere to the same high standard
of services as those provided by conventional care, with the
addition of integrating selected complementary therapies.
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safe and effective health care with as few side effects as
possible [14]. Integrated health services are increasingly
becoming part of international and national health care pol-
icy and research agendas [15–19], and recommendations
for integrative care strategies can be found in national care
guidelines relating to mental and physical disorders such as
depression and chronic pain whereby for example mindful-
ness, massage and manual therapy may be included in the
care for certain diagnoses [20, 21].
Anthroposophic integrative care (AIC) is a well-
established form of integrative health service provision
provided by conventionally trained medical doctors,
nurses and therapists that have additional training in
the practice and integration of selected complemen-
tary therapies such as massage, natural remedies, art,
music and movement therapies together with conven-
tional therapies [22]. Recently, the Swiss government
reported primarily positive outcomes, few risks, good
tolerability and favourable cost structure, together
with high patient satisfaction of AIC [23]. Similarly,
Swedish research has indicated improved patient reported
outcome measures of quality of life and self-rated health,
following AIC for SRMD [24] and that pain patients that
have received AIC may reduce their need of analgesics
[25]. AIC is implemented in numerous hospitals and med-
ical practices internationally [23, 26]. In Sweden, patients
have been referred to AIC rehabilitation at Vidarkliniken,
the largest Scandinavian anrthroposophic hospital, since
the 1980s [22, 27]. The majority of large county councils
in Sweden have caregiving agreements with Vidarkliniken
that allow for referrals of SRMD patients to inpatient AIC
on similar terms as referrals of SRMD patients to inpatient
conventional care (CC). Referral of SRMD patients to
inpatient care, whether AIC or CC, are typically man-
aged via general practitioners in primary care.
Given the common practice of integrative care in
private and public health settings, scientific studies
investigating different health care models are needed
to inform decision-making and health sector reform.
The randomised placebo controlled trial is the gold
standard for the evaluation of specific efficacy, for
instance of newly regulated drugs. Comparative effect-
iveness research, including pragmatic clinical trials
and registry evaluations, where different interventions
are evaluated, compared and contrasted under normal
clinical circumstances, is an evaluation approach that is
increasingly recommended by Health Technology Assess-
ment boards in the strive for more valid and generalizable
outcomes to clinical health care provision [28–31]. Sweden
has comprehensive population based health registries
accessible to researchers, which makes registry studies in
Sweden a valid and cost-effective method of research. The
aim of this study was to explore and contrast theprescription of first-line drugs for SRMD patients referred
to hospital inpatient AIC or inpatient CC.
Methods
Design and setting
Retrospective registry study, Stockholm County, Sweden.
Patient observations and matching
Patients with SRMD that had been referred to the
largest inpatient AIC hospital in Sweden (Vidarkliniken)
were identified through the high-quality inpatient regis-
try (patientregistret för slutenvård) of Stockholm County
Council for the period 2005–2010. The same registry
and periods were used to identify SRMD patients that
had been referred to inpatient CC, which were matched
to the AIC patients by available background characteris-
tics including:
 diagnosis (International Classification of Diseases,
version 10: code F43),
 age at index visit (18–39 years, 40–49 years, 50–59
years, and 60+),
 gender (male/female) and
 socio-economic group (three classes: High,
Affluence and Low).
The latter was achieved by utilizing the Mosaic geo-
demographic segmentation system employed by Stockholm
County Council [32]. The Mosaic system makes use of a
multivariate statistical classification technique for categoriz-
ing the population into different socio-economic groups
[33]. It relies mainly on data from Statistics Sweden with its
high-quality population registries, including the Swedish
Population Register, the Real Estate Tax Register, the In-
come and Wealth Register, the Register of Education and
data from parliamentary elections [33, 34]. There are thou-
sands of Mosaic geographic areas in Sweden, which implies
high accuracy without the risk of detrimental effects on the
integrity of individual data protection [33]. Based on the
available subgroup sizes for matching, the patients of the
CC cohort were randomly sampled in a 1:10 proportion to
AIC patients to ensure a balanced sample representative of
the totality of provided CC.
Index visit, target diagnosis and care provision
The index visit was defined as the first registered
inpatient visit to AIC or CC with the target SRMD
diagnosis (ICD-10: F43), which by description entails
reaction to severe stress and adjustment disorders, i.e.
referring to long- or short-term reactions caused by
exposure to severe stress. The F43 diagnosis class
accommodates acute and post-traumatic stress disor-
ders, adjustment disorders – with brief or extended
depressive reactions, anxiety or other emotional
Sundberg et al. BMC Complementary and Alternative Medicine  (2015) 15:354 Page 4 of 11disturbances – and other reactions to severe stress
such as exhaustion disorder [1, 2]. Patients referred to in-
patient CC did not received inpatient AIC, and patients
referred to inpatient AIC had not previously been regis-
tered for inpatient CC for the same target diagnosis. Li-
censed caregivers providing inpatient AIC in Sweden
typically have dual proficiency, which means they are
trained in both conventional therapies (e.g. medicine or
nursing) and anthroposophic complementary therapies
(e.g. natural remedies, massage, art and music therapy).
Thus, Swedish inpatient AIC provision typically consists
of a personalized integration of conventional and anthro-
posophic complementary therapies.
Outcomes and data collection
The primary outcomes were:
i. the changes in prescribed and sold defined daily
doses (DDD)—a term referring to the assumed
average maintenance dose per day for a drug used
for its main indication [35]; and
ii. the associated costs of the prescribed drugs.
The study outcomes were investigated over 180-days
and 360-days time periods, i.e. the data for 90 days be-
fore/after and for 180 days before/after, the index visits
to AIC or CC, respectively. Data on drug prescriptions,
purchased DDD and costs in Swedish kronor were col-
lected for 2005 to 2010 from the Swedish Prescribed
Drug Register, which is operated and controlled by the
National Board of Health and Welfare (Socialstyrelsen),
a Swedish government agency under the Ministry of Health
and Social Affairs [36]. The cost of drugs was converted
from Swedish kronor to EUR using the average exchange
rate during 2013 corresponding to nine Swedish kronor to
one EUR. All costs were expressed in 2013 year’s prices
using the Swedish consumer price index for recalculations
as necessary. The selected drug groups and combina-
tions were restricted to those covered by the Anatom-
ical Therapeutic Chemical classification system [37], i.e.
codes N05A (antipsychotics), N05B (anxiolytics), N05C
(hypnotics and sedatives) and N06A (antidepressants),
which includes codes relevant to first-line drugs recom-
mended in the management of SRMD in Sweden [13]. Up
to four substrings were applied to define the selected ATC
groups. The derived DDD rate per patient, per day and
per period, was based on the number of AIC and CC pa-
tients in the study sample.
General disease load/co-morbidity was estimated by
frequency and mean value analysis of ICD-10 chapter
data (A-Z) based on registered inpatient visits 365-
days before and after the first inpatient visits for ICD-
10: F43 (index). The target SRMD diagnosis ICD-10:
F43 was included in chapter F that details “Mental andbehavioural disorders”. Differences of derived frequen-
cies per diagnostic category were calculated between
the cohorts by using the attributable difference as a
simple and reliable approach.
Statistical analysis
Standard statistical procedures were employed for calcu-
lating means, standard deviations and 95 % confidence
intervals. Data was initially tested for normal distribu-
tion and as some violation was detected, mainly in cost
data, these were submitted to both parametric and non-
parametric testing procedures. However, as satisfaction
with the required criteria for normality was partially met,
parametric tests were deemed most appropriate to provide
generalizable findings. Although this study relies on para-
metric methods to generate conclusions, non-parametric
Wilcoxon rank sum testing was also employed to provide
sensitivity testing for robustness and reliability of results.
While Chi-square test was used for the categorical
background variables, paired and unpaired t-tests were
performed to test for differences between means of con-
tinuous variables, i.e. the DDDs and costs of drugs for the
cohorts over time. Differences in disease load were tested
at baseline and follow-up periods by t-test and Poisson re-
gression methods. All statistical tests were two-tailed and
corrected for unequal group variances as necessary.
Cohen’s d was used to estimate the effect sizes with 95 %
CI between the cohorts, ranging from small (d = 0.2), to
medium (d = 0.5), to large (d = 0.8) effect sizes [38]. The
level of statistical significance was 5 % (two-tailed test).
Statistical software included SAS and STATA13.
Ethics statement
The study was approved by the Regional Ethics Committee
in Stockholm. Data was retrieved as de-identified/anon-
ymized files from the national and county council health
care registries, thus no written informed consent proce-
dures were conducted. Results were only analysed and
reported at group level.
Results
There were no statistically significant differences between
the matched AIC (n = 161) and CC (n = 1571) cohorts in
terms of observable background characteristics (Table 1)
and the cohorts had similar overall disease loads the year
preceding the index visit (Table 5). The prescription of
first-line anxiolytics and antidepressants were not statisti-
cally different between groups at baseline, whereas the
prescription of antipsychotics and hypnotics/sedatives
were significantly lower for the AIC cohort both at the 90
and 180 days pre-index visit periods (Table 2). The subse-
quent changes of drug prescriptions and costs during the
investigated periods, i.e. 90-days before/after and 180-days
before/after the index visit, showed a general decrease
Table 1 Characteristics of the integrative care and conventional care patient cohorts
Integrative Care (N = 161) Conventional Care (N = 1571) Statistical
difference
(P-value)
% (n) % (n)
Gender 0.927
Female 91.3 (147) 91.1 (1431)
Male 8.7 (14) 8.9 (140)
Age 0.995
0–39 years 19.9 (32) 19.1 (300)
40–49 years 38.5 (62) 39.2 (615)
50–59 years 29.2 (47) 29.0 (456)
60+ years 12.4 (20) 12.7 (200)
Socio-economic classification (Mosaic) 0.953
High 50.9 (82) 52.2 (820)
Affluent 17.4 (28) 18.5 (290)
Low 29.8 (48) 29.3 (461)
Missing 1.9 (3) 0
All patients were diagnosed with code F43 according to the International Classification of Diseases version 10. Analyses by Chi-square test
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xiolytics and hypnotics/sedatives (Tables 3 and 4). Within
the CC cohort there was an observed general increase of
prescriptions and costs of first-line drugs during the same
time periods (Tables 3 and 4). Figure 1 contrasts theTable 2 Drug prescriptions and cost of drugs 90 and 180 days befo
integrative care and conventional care cohorts
Integrative Care (N = 161)
DDD/patient
ATC-N05A 90-days before 0.8 (−0.1 to 1.7)
ATC-N05B 90-days before 26.5 (16.6 to 36.3)
ATC-N05C 90-days before 5.7 (3.5 to 7.9)
ATC-N06A 90-days before 16.6 (9.6 to 23.7)
ATC-N05A 180 days before 1.3 (−0.01 to 2.7)
ATC-N05B 180 days before 41.4 (25.8 to 57.1)
ATC-N05C 180 days before 10.7 (6.9 to 14.5)
ATC-N06A 180 days before 33.5 (20.1 to 46.7)
Cost/patient (EUR)
ATC-N05A 90-days before 5.4 (−0.3 to 11.1)
ATC-N05B 90-days before 4.8 (2.9 to 6.6)
ATC-N05C 90-days before 4.9 (3.0 to 6.8)
ATC-N06A 90-days before 27.5 (14.6 to 40.4)
ATC-N05A 180 days before 6.8 (−0.3 to 13.9)
ATC-N05B 180 days before 7.6 (4.5 to 10.7)
ATC-N05C 180 days before 8.2 (5.3 to 11.2)
ATC-N06A 180 days before 50.3 (28.5 to 72.1)
DDD, Defined daily dose. EUR, euro. Drug categories according to the Anatomical T
anxiolytics; N05C, hypnotics and sedatives; and N06A, antidepressants. Average (95changes of drug utilisation within the AIC and the CC
cohorts over time.
The effect sizes expressed as Cohen’s d ranged from
small to medium (Tables 3 and 4). The drug prescriptions,
expressed in DDD/1000 patients/day, were higher for there the first observed inpatient visit with diagnosis F43 for the
Conventional Care (N = 1571) Statistical difference (P-value)
2.9 (2.1 to 3.8) <0.001
32.3 (27.9 to 36.7) 0.287
11.9 (10.5 to 13.3) <0.001
21.0 (18.2 to 32.8) 0.260
5.1 (3.7 to 6.5) <0.001
54.2 (46.4 to 61.9) 0.150
20.6 (18.1 to 23.0) <0.001
37.3 (32.6 to 42.0) 0.592
19.4 (13.8 to 24.9) <0.001
6.4 (5.5 to 7.2) 0.133
8.4 (7.4 to 9.4) 0.002
24.8 (21.3 to 28.2) 0.699
36.5 (26.9 to 46.2) <0.001
11.4 (9.8 to 13.0) 0.036
14.7 (12.8 to 16.5) <0.001
46.1 (40.3 to 51.9) 0.722
herapeutic Chemical (ATC) classification system: N05A, antipsychotics; N05B,
% confidence interval) values. Analyses by t-tests (two tailed)
Table 3 Change in drug prescriptions and cost of drugs during 90 days before/after the first observed inpatient visit with diagnosis
F43 for the integrative care and conventional care cohorts
Integrative Care (N = 161) Conventional Care (N = 1571) Conventional-Integrative Conventional-Integrative
Change from 90-days before to 90-days after index visit Difference in change between groups Effect Size (Cohen’s d)
DDDs/patient
ATC-N05A −0.3 (−1.1 to 0.6), p = 0.518 0.7 (−0.2 to 1.6), p = 0.147 1.0 (−0.3 to 1.5), p = 0.515 0.1 (−0.1 to 0.2)
ATC-N05B −11.5 (−19.7 to −3.2), p = 0.003 16.9 (12.4 to 21.3), p < 0.001 28.3 (14.2 to 42.4), p < 0.001 0.3 (0.2 to 0.5)
ATC-N05C −2.1 (−3.6 to −0.6), p = 0.004 6.8 (5.5 to 8.1), p < 0.001 8.9 (4.8 to 13.0), p < 0.001 0.4 (0.2 to 0.5)
ATC-N06A −2.1 (−7.8 to 3.6), p = 0.473 10.4 (7.8 to 13.0), p < 0.001 12.5 (4.2 to 20.8), p < 0.001 0.2 (0.1 to 0.4)
Cost/patient (EUR)
ATC-N05A 5.3 (−11.9 to 22.6), p = 0.542 14.5 (7.7 to 21.4), p < 0.001 9.2 (−12.9 to 31.3), p = 0.415 0.1 (−0.1 to 0.2)
ATC-N05B −2.4 (−4.1 to −0.7), p = 0.003 3.2 (2.3 to 4.2), p < 0.001 5.6 (2.6 to 8.7), p < 0.001 0.3 (0.1 to 0.5)
ATC-N05C −2.2 (−3.5 to −0.8), p = 0.001 2.9 (2.1 to 3.7), p < 0.001 5.1 (2.4 to 7.7), p < 0.001 0.3 (0.2 to 0.5)
ATC-N06A −9.2 (−20.6 to 2.3), p = 0.058 13.0 (9.1 to 16.9), p < 0.001 22.2 (9.4 to 34.9), p < 0.001 0.3 (0.1 to 0.4)
DDD, Defined daily dose. EUR, euro. Drug categories according to the Anatomical Therapeutic Chemical (ATC) classification system: N05A, antipsychotics; N05B,
anxiolytics; N05C, hypnotics and sedatives; and N06A, antidepressants. Average (95 % confidence interval), p values; Analyses by t-tests (two tailed). Cohen’s d:
small 0.2, medium 0.5, large 0.8
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82.2, Antidepressants 19.7, Hypnotics and sedatives 17.4,
for the 90 days period and; Anxiolytics 112.3, Antidepres-
sants 60.3, Hypnotics and sedatives 31.4 for the 180 days
period. Correspondingly, the costs of these drugs, expressed
as cost/1000 patients/day, were higher for the CC cohort:
Antidepressants EUR 65.4, Anxiolytics EUR 16.9, Hyp-
notics/sedatives EUR 15.5 (90-days period); and Antide-
pressants EUR 96.0, Anxiolytics EUR 20.3, Hypnotics/
sedatives EUR 20.2 (180-days period).
The overall disease load based on all registered ICD-
10 diagnostic chapters (A-Z) was similar at baseline and
generally stable for both cohorts over time, with one
notable exception, the CC cohort had increased visits
with an ICD-10 F-chapter diagnosis, which coversTable 4 Change in drug prescriptions and cost of drugs during 180
F43 for the integrative care and conventional care cohorts
Integrative Care (N=161) Conventional Care (N=157
Change from 180-days before to 180-days after index visit
DDDs/patient
ATC-N05A −0.2 (−1.6 to 1.2), p = 0.767 2.0 (0.5 to 3.5), p = 0.004
ATC-N05B −15.3 (−26.7 to −3.8), p = 0.004 27.2 (20.3 to 34.1), p < 0.00
ATC-N05C −3.8 (−6.4 to −1.2), p = 0.002 12.3 (10.1 to 14.5), p < 0.00
ATC-N06A −7.4 (−18.4 to 3.5), p = 0.091 22.5 (17.4 to 27.5), p < 0.00
Cost/patient (EUR)
ATC-N05A 12.8 (−13.9 to 39.5), p = 0.345 25.7 (14.8 to 36.5), p < 0.00
ATC-N05B −2.8 (−4.7 to −0.8), p = 0.003 4.5 (3.0 to 6.0), p < 0.001
ATC-N05C −2.7 (−4.6 to −0.9), p = 0.002 5.4 (3.9 to 6.9), p < 0.001
ATC-N06A −12.6 (−31.1 to 5.9), p = 0.181 27.9 (21.3 to 34.6), p < 0.00
DDD, Defined daily dose. EUR, euro. Drug categories according to the Anatomical T
anxiolytics; N05C, hypnotics and sedatives; and N06A, antidepressants. Average (95
small 0.2, medium 0.5, large 0.8mental and behavioural disorders, the year after the
index visit (Table 5).
Discussion
The current study set out to explore and contrast the
prescription of first-line drugs for SRMD patients referred
to hospital inpatient AIC or inpatient CC. The overall
prescription pattern within each cohort showed a general
decrease for the AIC cohort and an increase for the CC
cohort. Notably, the retrospective study design doesn’t
allow for any causative conclusions of the reasons for the
observed trends. Accordingly, the study findings may ra-
ther be used for discussing and generating hypothesis of
potential differentiating factors that may have influenced
the drug outcomes within each cohort over time. Heredays before/after first observed inpatient visit with diagnosis
1) Conventional-Integrative Conventional-Integrative
Difference in change between groups Effect size (Cohen’s d)
2.2 (−2.4 to 6.8), p = 0.351 0.1 (−0.1 to 0.2)
1 42.5 (20.6 to 64.4), p < 0.001 0.3 (0.2 to 0.5)
1 16.1 (9.2 to 22.9), p < 0.001 0.4 (0.2 to 0.5)
1 29.9 (13.7 to 46.1), p < 0.001 0.3 (0.1 to 0.5)
1 12.9 (−22.1 to 47.8), p = 0.471 0.1 (−0.1 to 0.2)
7.2 (2.5 to 12.0), p = 0.003 0.3 (0.1 to 0.4)
8.1 (3.5 to 12.7), p < 0.001 0.3 (0.1 to 0.5)
1 40.5 (18.9 to 62.1), p < 0.001 0.3 (0.1 to 0.5)
herapeutic Chemical (ATC) classification system: N05A, antipsychotics; N05B,
% confidence interval), p values; Analyses by t-tests (two tailed). Cohen’s d:
Fig. 1 Change in drug prescriptions from 180-days before to 180-days after first observed inpatient visit with diagnosis F43 within the integrative
care and conventional care cohorts respectively. DDD, Defined daily dose. Drug categories according to the Anatomical Therapeutic Chemical
(ATC) classification system
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e.g. different management strategies between AIC and CC
providers, different SRMD disease severities and different
preferences of patients referred to AIC and CC, as well as
unknown confounders and selection bias, which may all
have influenced the observed drug outcomes.
One hypothesis is that AIC management, by integrating
complementary health approaches, may be able to help
SRMD patients better cope with their disorder at the same
time relying less on the use of prescription pharmaceuticals.
Supporting this hypothesis is the increased health-related
quality of life and improved and self-rated health that has
been reported for SRMD patients receiving this type of AIC
[24]. Similarly, emerging evidence of reduced utilisation of
pharmaceuticals and health resources have been reported
in previous studies of AIC and other types of integrative
care, e.g. lower prescription rates and less adverse drug
reactions relating to acute respiratory and ear infections
[39], reduced use of analgesics for pain patients in inpatient
[25] or primary care settings [40–42], and generally less use
of health care resources associated with integrative care
compared to conventional care [43].
On the other hand, it is currently unknown whether the
observed drug prescription patterns reflect a management
issue per se, e.g. that CC providers/patients may prioritize
pharmacotherapy over other types of treatment compared
to AIC providers/patients, or if the patients that were
referred to CC actually had more severe SRMD that moti-
vated more prescriptions of first-line drugs. Notably, despite
the use of high-quality registries, the data did not containinformation on duration, intensity or severity of disease.
Hence, despite the similar profiles of the integrative and
conventional cohorts at baseline, it is possible that conven-
tional patients either already had, or developed, more se-
vere SRMD over time and that the severity of disease may
influence e.g. referral mechanisms or drug prescription pat-
terns. The relative increase for CC patients in the frequency
of registered inpatients visits in the ICD-10 F chapter for
mental and behavioural disorders is an indication reflecting
this possibility. However, the overall disease load was gener-
ally stable and similar within both cohorts over time, al-
though the AIC cohort had somewhat decreased visits in
the F chapter the year after the first visit. Thus, in that
sense, the reduced usage of medication seems to not have
negatively impacted on the disease load of the AIC patients.
The relative decline in F-chapter disease burden for AIC
patients observed in the current study may point towards
potential cost savings with AIC for SRMD rehabilitation.
However, it is important to acknowledge that the fre-
quency of visits relating to diagnostic chapters of regis-
tered inpatient visits per se is not necessarily equal to a
decrease in the use of health care resources. Importantly,
factors such as total length of hospital stay, use of out-
patient or specialist care and sick-leave, also need to be
accounted for.
Drugs can be of tremendous benefit when properly pre-
scribed and tolerated. However, if they are not rationally
used, and for too long periods, and especially if there is in-
adequate scientific evidence to inform appropriate clinical
integration of pharmacological care [44–46], the prospect of
Table 5 Number of ICD-10 diagnostic categories (A-Z) per patient based on registered inpatient visits 365-days PRE/POST first visit
for F43 (index visit)
Integrative care (n 161) Conventional care (n 1571) Conventional-Integrative
365 days PRE Change 365 days POST 365 days PRE Change 365 days POST Attributable difference in change between groups
ICD-10 category
A 0.05 0.02 0.06 0.02 0.00
B 0.13 −0.06 0.19 −0.04 0.02
C 0.24 0.30 0.31 0.14 −0.16
D 0.30 −0.16 0.19 0.02 0.18
E 0.28 0.13 0.41 0.03 −0.10
F 5.94 −1.24 6.22 5.90 7.14
G 0.27 −0.06 0.25 −0.01 0.05
H 0.27 −0.11 0.22 0.06 0.17
I 0.58 −0.16 0.52 0.05 0.21
J 0.53 −0.09 0.45 −0.05 0.04
K 0.36 −0.14 0.32 −0.02 0.11
L 0.20 0.02 0.18 0.01 −0.01
M 0.82 0.02 0.92 −0.02 −0.05
N 0.31 0.04 0.44 0.06 0.02
O 0.05 −0.02 0.13 −0.01 0.01
P 0.00 0.00 0.00 0.00 0.00
Q 0.01 0.00 0.02 0.00 0.00
R 0.99 −0.16 1.12 −0.08 0.09
S 0.30 −0.06 0.26 0.15 0.20
T 0.09 0.01 0.33 0.04 0.03
U 0.00 0.00 0.00 0.00 0.00
V 0.00 0.01 0.01 −0.01 −0.02
W 0.06 0.02 0.08 0.02 0.00
X 0.01 0.04 0.09 0.07 0.03
Y 0.01 0.03 0.06 0.00 −0.03
Z 1.56 0.18 1.69 0.31 0.13
ICD-10, International Classification of Diseases version 10. Main diagnostic category F (Mental and behavioural disorders) in bold
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the use of pharmacotherapy may be a worthwhile incentive.
Clearly, improved rational use of drugs would result in
fewer adverse drug reactions. It has been estimated that
15 % of all reported adverse drug events are caused by
drugs in the Anatomical Therapeutic Chemical “N” cat-
egory, where 60 % are caused by antipsychotic, anxiolytic,
hypnotic and sedative and antidepressant drugs [47]. Close
to 40 % of these reported adverse drug events were deemed
serious, and over 40 % were unexpected [47]. Notably, the
majority of the referred AIC patients where women, who
generally may be affected to a greater extent by adverse
drug reactions than men. Specified side effects range from
nervous systems complaints such as headache, tremor and
dizziness, over psychiatric conditions including insom-
nia and restlessness, to gastrointestinal problems withnausea and dryness of mouth, and increased weight
[47]. Principally, reduced usage of prescription drugs,
as was observed within the AIC cohort, could be asso-
ciated with worse outcome. However, this is unlikely
as the results also indicate, in addition to previous
research findings showing likely health benefits with
AIC, a concomitant reduction in the frequency of regis-
tered inpatient medical services (ICD-10:F chapter) for the
AIC cohort. Future and prospective follow-up studies
should address this issue by including drug utilization as
well as clinical outcome and adverse event data.
The total cost for mental ill health including SRMD in
Sweden is substantial and estimated to be in the range of
EUR 10 billion [10]. However, the total direct cost estimate
of all types of health care utilisation, including the cost of
drugs, is only a small fraction - up to 20 % - of the total
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cost of first-line drugs for patients referred to AIC was
consistent and significant. Findings from the 180-days
follow-up cohort in this study speculate that, an estimated
value of EUR 137 per 1000 patients per day in costs of
drugs could potentially be waived if AIC replaces conven-
tional SRMD care. Although these figures are merely
hypothetical and may seem rather small per patient, they
could have significant impact over time considering a lar-
ger population suffering from SRMD. For example,
employing the above estimates, a health insurer caring for
one thousand SRMD patients could hypothetically save
approximately EUR 50 000 per year in direct costs of first-
line drugs alone by implementing AIC. Such impacts may
be of interest to policy makers and health insurers alike.
Nonetheless, such cost savings might not be perceived by
e.g. patients and prescribing physicians, as there is a
national insurance policy with an upper limit for what
patients have to pay themselves per year for pharmaceuti-
cals in Sweden.
The current consensus recommendations for SRMD
rehabilitation include multi-modal care, which might
include both pharmacological and physiological inter-
ventions [2, 12, 13]. However, SRMD rehabilitation may
be complex both to formulate and evaluate, and the
care process of deciding which treatments to combine
in the rehabilitation of individual patients may not be
straightforward. Antidepressants may be prescribed as
pharmacotherapy option for treating depressive reactions
in SRMD patients [13], but may also be prescribed in the
management of anxiety and pain disorders [48, 49]. There
is some evidence for the selective use of pharmacotherapy
for SRMD, e.g. selective serotonin reuptake inhibitors in
the treatment of patients suffering from post-traumatic
stress disorders compared to placebo [50]. However,
there remain crucial knowledge gaps in the evidence,
e.g. whether or not to combine pharmacotherapy with
other types of interventions including psychological
therapies or for how long pharmacological treatment is
clinically warranted. Clearly, one of the main challenges
in the management of SRMD patients is to determine
appropriate combinations of therapies that can be ap-
plied in the care of each individual patient.
The World Health Organization, through authoritative
recommendations [18] and World Health Assembly reso-
lutions [19], currently suggest member states to implement
integrative care approaches within their national health
systems. The strive for a salutogenic approach, where each
patient encounter may be interpreted as a unique oppor-
tunity to collaboratively engage in a personalized patient-
centred holistic healing process, may empower caregivers
and patients alike in finding additional care strategies to
pharmacotherapy [23, 42, 51] and lead to patients taking
more responsibility for their own health [42, 51]. AIC hasbeen suggested to facilitate new attitudes towards change
and improved lifestyle habits that may improve patients’
health over time [52]. However, currently the knowledge
base of the generalizability and patient preferences of AIC
as well as the specific efficacy of individual and combina-
tions of therapies and products are generally lacking. The
academic underpinnings about the theoretical concepts of
contemporary AIC may also need further clarifications to
facilitate evidence informed communication and education.
Nonetheless, taken together the emerging evidence for
SRMD patients being referred to AIC seem to demonstrate
health benefits such as increased health-related quality of
life and self-rated health, together with reduced prescription
drug utilisation and associated costs, which merit consider-
ation for future research and evidence informed health sec-
tor reform.
Limitations
Although Swedish health care registries are generally of
very high standards with rigorous procedures, a problem
is the inability to ensure proper and complete reporting
from hospitals and health care units into the registries.
This type of uncontrollable factors, e.g. under-reporting
of co-morbid symptoms and disorders, including the
level of accuracy in diagnostic criteria, may have meth-
odological implications. Similarly, the selected SRMD
diagnosis code ICD-10: F43 is rather wide, encompassing
several different subgroups, each with unique aspects.
However, such imprecisions can be considered to occur
across all carers and patients and thus may be consid-
ered random noise. Specifically, the descriptive findings
of concurrent overall disease load did not show any visu-
ally apparent differences at baseline between AIC and
CC patients. A major methodological limitation was the
lack of detailed information about SRMD duration, on-
set and severity of symptoms in the registry data and
also that there were no specific details of the individual
treatment plans in the registries for either CC or AIC.
Further, using a retrospective cohort study design, which
is mainly hypothesis generating, the utilisation of AIC
and prescription of pharmaceuticals is likely based on
patient and provider preferences with a risk for selection
bias. Ideally, a prospective randomized clinical trial design
is needed to properly address such concerns. Similarly, the
reported differences in usage of drugs in this study might
be due to other unknown factors and confounders, such as
patient education or life-style choices, which were not pos-
sible to assess in the data or the matching procedure. While
this may be true, the argument may be inapt for real-life
decision-making, where patients can choose their type of
care and the question arises which costs and benefits are
associated with such choice. Based on the observed results
within the AIC cohort over time it may be hypothesized
that prescriptions and costs of first-line drugs decrease for
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are likely. However, the generalizability of such hypothesis
beyond the current setting is unknown despite that AIC
can be found in many countries internationally. Multi-
centre randomized clinical trials would be needed to inves-
tigate and examine such possibilities.
In the analysis, both DDD and cost outcomes data
showed some positive skewness when investigated by
Shapiro-Wilk and Kurtosis tests, albeit the skewness
was minimal for the DDD. Hence, we principally main-
tained parametric testing procedures, alongside some
non-parametric tests, in the analyses. Similarly, at 90
and 180 days before index there were some baseline
differences in terms of DDD and cost data of two drug
categories. Although different statistical modifications
may be considered to adjust for such differences, it
was not deemed necessary, as the primary interest was
to explore the change scores within groups over time,
and secondary to contrast the differences between the
cohorts.
Future research
Future prospective clinical trials in the area of conven-
tional and integrative management of SRMDs are clearly
warranted and should consider adverse events, tolerability
of care as well as control for any additional interven-
tions outside the health system, such as the use of
non-prescription drugs and self-care measures along-
side other clinical outcome measurements. Clinical in-
vestigations of integrative care have typically evaluated
the specific efficacy of various therapies in isolation. In
contrast, the comparative effectiveness of different
packages of care under pragmatic “real life” health care
situations is less well known. But such data increasingly
represent the basis on which health technology assess-
ment boards make recommendations. Given the preva-
lence and costs of SRMD and the emerging effects of
integrative care approaches on patient quality of life and
health economic measures, future studies may also con-
sider investigating the dose and duration of contributing
therapies, patient preferences, and determining factors
that predict response to care. The application of pragmatic
multi-centre clinical trial designs would facilitate
generalizability across locations and settings.
Conclusions
The findings of the current study suggests that there are
different drug utilization patterns for SRMD patients
referred to AIC or CC. Different management strategies
between AIC and CC providers as well as different SRMD
disease severities and preferences of patients referred to
AIC and CC are hypothetical differentiating factors that
may have influenced the observed drug outcomes over
time. Additional studies including prospective andrandomized clinical trials are warranted to determine if
there is a causal link between referring patients to inpatient
AIC and reduced utilization of first-line drugs thereafter.
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